17577 results about "Oncology" patented technology

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

The disclosure provides compounds, e.g., compounds of Formulae (I)-(III), and their use in treating medical diseases or disorders, such as cancer. Pharmaceutical compositions and methods of making various indene compounds are provided. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor and a PD-1 inhibitor or a PD-L1 inhibitor.

The present invention is directed to the compounds of Formula (A) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor and an EGFR inhibitor.

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a RTK-MAPK pathway inhibitor and a compound of Formula (I).

Compounds that degrade of Src homology 2 domain-containing phosphatase 2 (SHP2); compositions comprising the same; and their use for treating cancer and other diseases or conditions mediated by SHP2.

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an immunomodulator inhibitor and a compound of Formula (I).

The invention relates to the technical field of data processing, and discloses a preoperative risk comprehensive assessment method and system for breast cancer and a storage medium. The method comprises the following steps: collecting clinical information and carrying out digital processing; segmenting the multi-modal image by using deep learning; analyzing a pathological section based on the image features; carrying out multi-level fusion modeling to obtain a risk heat map; performing digital twinborn simulation in combination with a knowledge graph; and dynamically processing the follow-up data to form a risk adjustment mechanism. According to the method, accurate quantification and individualized treatment decision making of the preoperative risk of the breast cancer patient are realized, and the prediction accuracy is improved.

The present invention provides methods of treating a cancer patient with an inhibitor of KRAS and an anti-CCR8 antibody. These methods are useful for treating a number of cancers, including pancreatic, colorectal, and lung cancers.

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

The invention relates to the field of biotechnology and medicine, and more particularly to a polypeptide having the amino acid sequence SEQ ID NO: 1 and being capable of inhibiting RAS-GTPase activity, to the use of said polypeptide to produce a drug for treating stomach cancer or rectal cancer in a dose of 0.81-3.00 mg / kg, as well as to a drug based on said polypeptide for the treatment of stomach cancer or rectal cancer, and to a method for treating stomach cancer or rectal cancer by intraperitoneally administering said drug to a subject in an amount of 150 ml twice at an interval of 7 days.

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

The present invention is directed to the compounds of Formula (IV) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as WRN inhibitors, and can be used in a method of treatment of cancer, in particular, the cancer is treatable by inhibition of WRN, and / or the cancer characterized by MSI-H and / or dMMR

The present invention relates to the use of a FAK inhibitor in preparing a drug to be jointly used with a KRAS G12C inhibitor to treat a tumor.

The present disclosure relates generally to methods for treating cancer with a KRAS inhibitor in combination with an immune checkpoint inhibitor, and more specifically to treating cancer with a pyridopyrimidine derivative in combination with a PD-1 or PD-L1 inhibitor.

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Disclosed is a system for detecting whether the breast cancer is benign or malignant based on multiple modalities, which comprises: an ultrasonomics model configured to extract breast tumor position information and breast tumor morphological features on the basis of an acquired grayscale breast ultrasound image, perform global interactive fusion on the breast tumor position information and breast tumor morphological feature information, and convert a Transformer encoder-based feature output into an output vector of the corresponding classification dimensions by means of a fully connected layer; a metabonomics model configured to obtain a metabolic fingerprint spectrogram and analyze the metabolic fingerprint spectrogram on the basis of a metabolic database and a predetermined significantly differential metabolite to obtain abnormal metabolic pathways, signal transduction pathways, and related biochemical reactions associated with breast cancer malignancy; and a detection module configured to perform joint modeling, based on the breast tumor position information, the breast tumor morphological features, and a peak value of the significantly differential metabolite of the breast cancer malignancy, to output a prediction result about whether the breast cancer is benign or malignant.

The present invention relates to an early monitoring system for pancreatic cancer based on big data, including a data acquisition module, a feature extraction module, a risk assessment module and an early warning trigger module. The data acquisition module is used to obtain the user's laboratory test data, imaging test data and clinical symptom data. The feature extraction module is connected to the data acquisition module, and constructs a comprehensive feature vector by extracting biochemical indicator features, imaging features and symptom features. The risk assessment module uses a pre-trained deep learning model to analyze the feature vector and generate a pancreatic cancer risk probability. The early warning trigger module compares the risk probability with a preset threshold, generates an early warning signal when the risk probability exceeds the threshold, and pushes it to a medical service terminal to suggest further diagnosis. The present invention combines multimodal data and deep learning technology to achieve accurate early monitoring of pancreatic cancer and improve diagnostic efficiency and accuracy.

Provided are a compound represented by formula (I) and a pharmaceutical composition comprising the compound, and a use of a compound of formula (A) for preventing and / or treating cancer, tumor, inflammatory disease, autoimmune disease, or immune-mediated disease.

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and / or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The invention discloses a multi-omics pathological analysis system and method for colorectal cancer liver metastasis risk prediction, and relates to the technical field of biomedicine and cancer diagnosis, the system comprises a data acquisition module, a data preprocessing module, a cell analysis module, a score construction module, a model construction and training module and a prediction and evaluation module; according to the method, multiple omics data including the single cell data set, the space transcriptome data, the batch RNA-seq data, the clinical data and the full slice image WSIs are integrated, comprehensive and accurate prediction of the colorectal cancer liver metastasis risk is achieved, cross-dimensional data fusion and analysis improve the prediction accuracy and reliability, and the risk of the colorectal cancer liver metastasis is reduced. The invention also provides a powerful tool for deeply exploring the molecular mechanism of tumorigenesis, development and metastasis, and particularly in a cell analysis module, cell subtypes and molecular characteristics closely related to liver metastasis can be disclosed by identifying and analyzing malignant cell subgroups LMTMCs triggering liver metastasis, so that the liver metastasis can be discovered. And a scientific basis is provided for formulating a personalized treatment scheme.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

The present disclosure features a combination therapy useful for the treatment of solid tumors.